Viridian Therapeutics, Inc.\DE: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Viridian Therapeutics Inc. in a Schedule 13G filing with the SEC (accession 0000093751-26-000744). The filing signals that the institutional investor has crossed the key 5% threshold that triggers disclosure obligations for beneficial owners. Viridian, a clinical-stage biotech developing therapies for autoimmune and rare diseases, now counts State Street among its major institutional holders. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G or 13D amendments to see whether State Street's position is passive or active and whether it continues to build.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Viridian Therapeutics, Inc., STATE STREET CORP